4.6 Article

The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries

Related references

Note: Only part of the references are listed.
Editorial Material Medicine, General & Internal

Ethical and Scientific Implications of the Globalization of Clinical Research

Seth W. Glickman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Book Multidisciplinary Sciences

Chronic diseases in developing countries - Health and economic burdens

Rachel Nugent

REDUCING THE IMPACT OF POVERTY ON HEALTH AND HUMAN DEVELOPMENT: SCIENTIFIC APPROACHES (2008)

Editorial Material Biochemistry & Molecular Biology

Metabolic phenotyping in health and disease

Elaine Holmes et al.

Review Immunology

Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412

C. M. Dayan et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)

Article Health Care Sciences & Services

The Indian and Chinese health biotechnology industries: Potential champions of global health?

Sarah E. Frew et al.

HEALTH AFFAIRS (2008)

Editorial Material Medicine, Research & Experimental

The calm after the cytokine storm: lessons from the TGN1412 trial

E. William St. Clair

JOURNAL OF CLINICAL INVESTIGATION (2008)

Editorial Material Medicine, General & Internal

Responsive research in developing countries

Nelson Sewankambo et al.

LANCET (2008)

Editorial Material Medicine, General & Internal

Justice in translation: from bench to bedside in the developing world

Alex John London et al.

LANCET (2008)

Editorial Material Biotechnology & Applied Microbiology

Chinese health biotech and the billion-patient market

Sarah E. Frew et al.

NATURE BIOTECHNOLOGY (2008)

Article Biotechnology & Applied Microbiology

India's health biotech sector at a crossroads

Sarah E. Frew et al.

NATURE BIOTECHNOLOGY (2007)

Letter Medicine, General & Internal

Research ethics committees in Africa: Building capacity

Solomon Benatar

PLOS MEDICINE (2007)

Article Biotechnology & Applied Microbiology

Virtual drug discovery and development for neglected diseases through public-private partnerships

S Nwaka et al.

NATURE REVIEWS DRUG DISCOVERY (2003)

Article Immunology

Streamlining the process & regulatory issues

D Birnkrant